Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors. Dr LeBeaut has broad experience in R&D, clinical development and research/medical affairs. He will optimally complement the Board to assess Vifor Pharma’s pipeline development and clinical programs aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”
Alexandre LeBeaut was formerly Chief Scientific Officer and Executive Vice-President R&D at Ipsen Bioscience Inc. with more than 25 years of extensive global R&D experience in the biopharmaceutical industry including Schering-Plough, Novartis, Sanofi, Axcan Pharmaceuticals and Bluebird Bio. Alexandre is a French and US citizen and a pediatrician who holds a M.D. from Paris University. He is a member of the Board of Calypso Biotech.
After 25 years with Vifor Pharma and four years of service on the Board of Directors, Dr Gianni Zampieri has decided that he will not stand for re-election to the Board at the Annual General Meeting in 2021. “With his expertise and valuable insights, Gianni Zampieri has been instrumental in the strategic development of the company in various roles. Because of his profound strategic foresight he drove the development and the launch of Ferinject, which is now a blockbuster product for the company.” As CEO for Vifor Pharma he successfully managed the separation of the group and the IPO of Galenica. Gilbert Achermann has also decided to step down from the Board of Vifor Pharma and therefore does not stand for re-election. “On behalf of the Board of Directors, I extend our sincere gratitude to both Directors for their excellent and successful work for Vifor Pharma, and we wish them all the best for their private and professional future” said Jacques Theurillat.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-PUMA-BIOTECHNOLOGY25.2.2021 22:09:06 CET | Press release
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
MOODY’S-ESG-SOLUTIONS25.2.2021 20:35:06 CET | Press release
Moody’s ESG Solutions Group: V.E Provides Second Party Opinion on Italy’s First Sovereign Green Bond Framework and Issuance
NC-INTL-ZINC-ASSOCIATION25.2.2021 19:50:05 CET | Press release
International Zinc Association Launches Zinc Battery Initiative
UT-MYHERITAGE25.2.2021 18:24:11 CET | Pressemeddelelse
MyHeritage udgiver banebrydende funktion for at animere ansigterne i stillbilleder
TX-HYOSUNG-TNS25.2.2021 17:02:06 CET | Press release
Hyosung TNS Invites Customers to ‘Be Inspired’ With New Campaign
CMT25.2.2021 16:27:12 CET | Press release
CMT’s New Report Confirms Increasing Appetite for Connected Insurance in Europe
ALPEGA-GROUP25.2.2021 16:02:09 CET | Press release
Alpega Group Showed Impressive Results In 2020
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom